Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
NCT05538897Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ipatasertib in endometrial cancer (EC), sponsored by National Cancer Institute. Started Mar 2023; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05538897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538897.